home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Conducting Effective Investigations of Atypical and Out of Specification Laboratory Results

 
  July 10, 2012  
     
 
ComplianceOnline, OnlineEvent
2012-07-31


Why Should You Attend:

Upon completion of this course the attendee should:

  1. Be familiar with various terms associated with investigations of atypical or out of specification results, and how to document those investigations.
  2. Be familiar with the FDA Guidance for Industry on Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production and how to apply it in laboratory situations.
  3. Be able to create a Laboratory Investigation Checklist and effectively document an investigation, including rationale and results.
  4. Know the importance of Corrective and Preventative Action (CAPA) and be able to identify appropriate CAPAs.
  5. Understand practical strategies to utilize outcomes from investigations for continuous improvement and reduction of future OOS results.

Areas Covered in the Seminar:

  • What Constitutes An Atypical or Out of Specification Result?
  • The Barr Decision of 1993 and Its Impact on OOS Investigations.
  • The FDA Guidance for Industry on Investigating OOS Test Results.
  • Reporting Data.
 
 
Organized by: Complianceonline
Invited Speakers:

Gregory Martin, is President of Complectors Consulting ( www.complectors.com ) which provides consulting and training in the area of Pharmaceutical Analytical Chemistry.  He has particular interest in QbD/Lean approaches to dissolution testing, impurity methods, method lifecycle (development/validation/transfer) and instrument qualification, and is passionate about using good science and sound logic to achieve high quality results, consistent with cGMPs, while minimizing resources.  Mr. Martin has over 25 years experience in the pharmaceutical industry and was Director of Pharmaceutical Analytical Chemistry (R&D) for a major PhRMA company for a number of years.  In addition, he has volunteered for the USP for over 10 years, and currently serves as Vice Chair of the General Chapters – Physical Analysis Expert Committee, and serves on Expert Panels on Validation and Verification, Weights and Balances and Use of Enzymes for Dissolution Testing of Gelatin Capsules.  He is also Chair-elect of the AAPS In Vitro Release and Dissolution Testing Focus Group.  He serves on the Editorial Advisory Board of the Journal of Validation Technology and Journal of GXP Compliance.  He can be contacted atgreg.martin@complectors.com .

 
Deadline for Abstracts: 2012-07-30
 
Registration:
$299.00
E-mail: referral@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.